FIELD: biotechnology.
SUBSTANCE: invention can be used in medical practice. The invention discloses a recombinant single chain chorionic gonadotropin polypeptide having an amino acid sequence encoding the beta chain and the alpha chain of equine chorionic gonadotropin linked to one or more sequences that include glycosylation sites, resulting in excellent in vitro and in vivo activity.
EFFECT: invention can be used in the preparation of a medicinal product for the treatment of pathological conditions related to reproduction or ovulation in mammals.
11 cl, 12 dwg, 8 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ADENOVIRUSES AND METHODS FOR ADENOVIRUS APPLICATION | 2019 |
|
RU2782528C1 |
| METHODS OF TREATING TISSUE CALCIFICATION | 2015 |
|
RU2770698C2 |
| RECOMBINASE MUTANTS | 2015 |
|
RU2721920C2 |
| CHIMERIC ANTIGEN RECEPTORS AIMED AT PSCA | 2016 |
|
RU2759879C2 |
| 1E10 MONOCLONAL MOUSE ANTIBODY 1E10 AND RECOMBINANT CHIMERIC (MOUSE-HUMAN) ANTIBODY XI1E10, NEUTRALIZING BACILLUS ANTHRACIS LETHAL TOXIN, AND A STRAIN OF HYBRID CULTURED ABIMAL CELLS -MUS MUSCULUS 1E10 | 2020 |
|
RU2745116C1 |
| RECOVERED NUCLEIC ACID WHICH CODES FVIII-BDD-BASED FUSION PROTEIN AND HETEROLOGOUS SIGNAL PEPTIDE, AND USE THEREOF | 2022 |
|
RU2818229C2 |
| CHLAMYDIA SP VACCINES | 2014 |
|
RU2723046C2 |
| VACCINE BASED ON AAV5 FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-CoV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2020 |
|
RU2783313C1 |
| VACCINE BASED ON AAV5 FOR THE INDUCTION OF SPECIFIC IMMUNITY TO THE SARS-CoV-2 VIRUS AND/OR THE PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2021 |
|
RU2761879C1 |
| AAV5-BASED VACCINE FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-COV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-COV-2 | 2020 |
|
RU2760301C1 |
